Compare Stocks: CMPX, CGEM, ORIC, and OMER

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$16.87 -22.2%	$19.85	$5.68 ▼ $23.19	$1.39B	0.02	895,414 shs	2.59 million shs
CMPX Compass Therapeutics	$1.17 -5.6%	$2.12	$1.13 ▼ $6.88	$223.31M	0.95	3.95 million shs	7.68 million shs
OMER Omeros	$20.74 -1.5%	$15.78	$4.05 ▼ $21.24	$1.52B	2.6	1.55 million shs	1.35 million shs
ORIC Oric Pharmaceuticals	$13.33 -1.3%	$12.68	$7.23 ▼ $14.93	$1.40B	1	1.22 million shs	1.72 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	+1.50%	+5.50%	-0.05%	+22.78%	+245.06%
CMPX Compass Therapeutics	-31.87%	-32.97%	-48.33%	-38.77%	-64.47%
OMER Omeros	+13.85%	+22.60%	+9.24%	+98.96%	+389.53%
ORIC Oric Pharmaceuticals	+6.55%	+9.22%	-4.93%	+43.16%	+24.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$16.87 -22.2%	$19.85	$5.68 ▼ $23.19	$1.39B	0.02	895,414 shs	2.59 million shs
CMPX Compass Therapeutics	$1.17 -5.6%	$2.12	$1.13 ▼ $6.88	$223.31M	0.95	3.95 million shs	7.68 million shs
OMER Omeros	$20.74 -1.5%	$15.78	$4.05 ▼ $21.24	$1.52B	2.6	1.55 million shs	1.35 million shs
ORIC Oric Pharmaceuticals	$13.33 -1.3%	$12.68	$7.23 ▼ $14.93	$1.40B	1	1.22 million shs	1.72 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	+1.50%	+5.50%	-0.05%	+22.78%	+245.06%
CMPX Compass Therapeutics	-31.87%	-32.97%	-48.33%	-38.77%	-64.47%
OMER Omeros	+13.85%	+22.60%	+9.24%	+98.96%	+389.53%
ORIC Oric Pharmaceuticals	+6.55%	+9.22%	-4.93%	+43.16%	+24.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	2.78	Moderate Buy	$33.00	95.61% Upside
CMPX Compass Therapeutics	2.82	Moderate Buy	$10.21	773.02% Upside
OMER Omeros	2.71	Moderate Buy	$34.00	63.93% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$20.18	51.40% Upside

Current Analyst Ratings Breakdown

Latest CMPX, CGEM, ORIC, and OMER Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CMPX Compass Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/23/2026	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00
9/23/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$4.00
9/23/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/23/2026	CMPX Compass Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$4.00
9/23/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$26.00
9/22/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$5.00 ➝ $1.00
9/22/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/22/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$22.00
9/14/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
CMPX Compass Therapeutics	$850K	247.89	N/A	N/A	$1.11 per share	1.05
OMER Omeros	N/A	N/A	$1.84 per share	11.25	($1.71) per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$219.88M	-$3.10	N/A	N/A	N/A	N/A	-52.89%	-48.18%	11/5/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	16.20	17.14	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)

Latest CMPX, CGEM, ORIC, and OMER Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	8.42	8.42
CMPX Compass Therapeutics	N/A	11.22	11.22
OMER Omeros	N/A	1.95	1.94
ORIC Oric Pharmaceuticals	N/A	13.19	13.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
CMPX Compass Therapeutics	68.43%
OMER Omeros	48.79%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	8.60%
CMPX Compass Therapeutics	18.70%
OMER Omeros	10.50%
ORIC Oric Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	109	64.36 million	58.82 million	Optionable
CMPX Compass Therapeutics	39	180.09 million	146.41 million	Not Optionable
OMER Omeros	175	72.39 million	64.79 million	Optionable
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable

CMPX, CGEM, ORIC, and OMER Headlines

Recent News About These Companies

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?

September 23 at 11:39 AM | marketbeat.com

BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target

September 23 at 9:00 AM | marketscreener.comM

Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at BTIG Research

September 23 at 8:05 AM | marketbeat.com

Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 5.02%

September 17, 2026 | aaii.comA

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch

September 15, 2026 | insidermonkey.com

WINTON GROUP Ltd Buys Shares of 83,000 Oric Pharmaceuticals, Inc. $ORIC

September 15, 2026 | marketbeat.com

Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC

September 13, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes Position in Oric Pharmaceuticals, Inc. $ORIC

September 8, 2026 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC

September 4, 2026 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 4, 2026 | marketbeat.com

Braidwell LP Acquires 86,500 Shares of Oric Pharmaceuticals, Inc. $ORIC

September 3, 2026 | marketbeat.com

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake

August 31, 2026 | ad-hoc-news.deA

BlackRock Inc. Buys Shares of 6,823,973 Oric Pharmaceuticals, Inc. $ORIC

August 31, 2026 | marketbeat.com

Dominic Piscitelli Sells 77,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

August 29, 2026 | insidertrades.com

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $1,054,130.00 in Stock

August 28, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes Position in Oric Pharmaceuticals, Inc. $ORIC

August 28, 2026 | marketbeat.com

Oric Pharmaceuticals, Inc. $ORIC Shares Bought by Algert Global LLC

August 26, 2026 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, CGEM, ORIC, and OMER Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$16.87 -4.80 (-22.15%)

Closing price 04:00 PM Eastern

Extended Trading

$17.38 +0.50 (+2.99%)

As of 07:58 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Compass Therapeutics NASDAQ:CMPX

$1.17 -0.07 (-5.65%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 0.00 (0.00%)

As of 07:50 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Omeros NASDAQ:OMER

$20.74 -0.31 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$20.70 -0.04 (-0.17%)

As of 07:31 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Oric Pharmaceuticals NASDAQ:ORIC

$13.33 -0.17 (-1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$13.32 -0.01 (-0.08%)

As of 07:30 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, CGEM, ORIC, and OMER Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, CGEM, ORIC, and OMER Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, CGEM, ORIC, and OMER Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, CGEM, ORIC, and OMER Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

Compass Therapeutics NASDAQ:CMPX

Omeros NASDAQ:OMER

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, CGEM, ORIC, and OMER Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, CGEM, ORIC, and OMER Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, CGEM, ORIC, and OMER Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, CGEM, ORIC, and OMER Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

Compass Therapeutics NASDAQ:CMPX

Omeros NASDAQ:OMER

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools